Clinical, genetic and quality-of-life study of a cohort of adult patients with tuberous sclerosis

被引:6
作者
De Sautu De Borbon, Elena Cristina [1 ]
Guerra Vales, Juan Manuel [1 ,2 ]
Lumbreras Bermejo, Carlos [1 ,2 ]
Guerrero Ramos, Felix [3 ]
Buj Padilla, Maria Jose [4 ]
Gonzalez de la Aleja, Jesus [5 ]
Morales Conejo, Montserrat [1 ,2 ]
机构
[1] Univ Hosp 12 Octubre, Dept Internal Med, Ave Cordoba S-N, Madrid 28041, Spain
[2] Univ Hosp 12 Octubre, Res Inst I 12, Ave Cordoba S-N, Madrid 28041, Spain
[3] Univ Hosp 12 Octubre, Dept Urol, Ave Cordoba S-N, Madrid 28041, Spain
[4] Univ Hosp 12 Octubre, Dept Radiol, Ave Cordoba S-N, Madrid 28041, Spain
[5] Univ Hosp 12 Octubre, Dept Neurol, Ave Cordoba S-N, Madrid 28041, Spain
关键词
Tuberous sclerosis; Adult; Quality of life; Multidisciplinary unit; DOUBLE-BLIND; COMPLEX; EVEROLIMUS; MANAGEMENT; TOSCA; RECOMMENDATIONS; MULTICENTER; REGISTRY; DISEASE; PHASE-3;
D O I
10.1186/s13023-021-01878-2
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background and objectiveTuberous sclerosis (TS) is a condition whose manifestations in childhood have been extensively described, but whose presentation in adults is less well known. This study describes the clinical and genetic characteristics, therapeutic management and quality of life of a cohort of adult patients with TS. A comparative study of the characteristics of patients diagnosed in childhood and adulthood is also carried out.Material and methodsThis observational, retrospective, cross-sectional study included a large cohort of adult patients (>= 16 years old) followed for 5 years in a specific rare diseases unit.ResultsFifty-seven patients with a diagnosis of tuberous sclerosis were included, more than 50% of whom were diagnosed as adults. The mean age of the patients was 42 years (20-86). The central nervous system was the main area affected (97%), followed by the skin (80.7%) and kidneys (73%). The most frequent genetic alteration was a mutation in the TSC2 gene (47.7%). Among patients diagnosed in adulthood, there was less neurological involvement, with less frequency of epileptic seizures (30.8% vs 60.79% of patients diagnosed in childhood) and astrocytomas (3.8% vs 53.6%), less intellectual disability (11.5% vs 71.4%) and less expressiveness of the condition. 42% of patients were treated with mTOR pathway inhibitors, and presence of an angiomyolipoma was the main indication. In a quality-of-life analysis, the means of the summary indices were below the scores of the average Spanish population: (47.42 (SD9.82) on the physical health scale, 45.61 (SD +/- 7.99) on the mental health scale) versus 50 (SD +/- 10) for the general population.Conclusions Up to 50% of adult patients with TS were diagnosed in adulthood, and the condition is less severe with less frequent epileptic seizures and intellectual disability. 42% require treatment with mTOR inhibitors, in most cases due to the presence of AMLs. The quality of life of adult patients with TS is diminished compared to the general population.
引用
收藏
页数:10
相关论文
共 35 条
  • [1] Alonso J, 1998, MED CLIN-BARCELONA, V111, P410
  • [2] Quality of life in patients with Tuberous Sclerosis Complex (TSC)
    Amin, Sam
    Mallick, Andrew A.
    Lux, Andrew
    O'Callaghan, Finbar
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2019, 23 (06) : 801 - 807
  • [3] A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report
    Auvin, Stephane
    Bissler, John J.
    Cottin, Vincent
    Fujimoto, Ayataka
    Hofbauer, Guenther F. L.
    Jansen, Anna C.
    Jozwiak, Sergiusz
    Kerecuk, Larissa
    Kingswood, J. Christopher
    Moavero, Romina
    Torra, Roser
    Villanueva, Vicente
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)
  • [4] Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study
    Bissler, John J.
    Kingswood, J. Chris
    Radzikowska, Elzbieta
    Zonnenberg, Bernard A.
    Belousova, Elena
    Frost, Michael D.
    Sauter, Matthias
    Brakemeier, Susanne
    de Vries, Petrus J.
    Berkowitz, Noah
    Voi, Maurizio
    Peyrard, Severine
    Budde, Klemens
    [J]. PLOS ONE, 2017, 12 (08):
  • [5] Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
    Bissler, John J.
    Kingswood, J. Christopher
    Radzikowska, Elzbieta
    Zonnenberg, Bernard A.
    Frost, Michael
    Belousova, Elena
    Sauter, Matthias
    Nonomura, Norio
    Brakemeier, Susanne
    de Vries, Petrus J.
    Whittemore, Vicky H.
    Chen, David
    Sahmoud, Tarek
    Shah, Gaurav
    Lincy, Jeremie
    Lebwohl, David
    Budde, Klemens
    [J]. LANCET, 2013, 381 (9869) : 817 - 824
  • [6] An update on the central nervous system manifestations of tuberous sclerosis complex
    Cotter, Jennifer A.
    [J]. ACTA NEUROPATHOLOGICA, 2020, 139 (04) : 613 - 624
  • [7] The tuberous sclerosis complex
    Crino, Peter B.
    Nathanson, Katherine L.
    Henske, Elizabeth Petri
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (13) : 1345 - 1356
  • [8] Neurological and neuropsychiatric aspects of tuberous sclerosis complex
    Curatolo, Paolo
    Moavero, Romina
    de Vries, Petrus J.
    [J]. LANCET NEUROLOGY, 2015, 14 (07) : 733 - 745
  • [9] Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs
    Dabora, SL
    Jozwiak, S
    Franz, DN
    Roberts, PS
    Nieto, A
    Chung, J
    Choy, YS
    Reeve, MP
    Thiele, E
    Egelhoff, JC
    Kasprzyk-Obara, J
    Domanska-Pakiela, D
    Kwiatkowski, DJ
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (01) : 64 - 80
  • [10] Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study (vol 13, 117, 2018)
    Ebrahimi-Fakhari, Daniel
    Mann, Lilian Lisa
    Poryo, Martin
    Graf, Norbert
    von Kries, Ruediger
    Heinrich, Beate
    Ebrahimi-Fakhari, Darius
    Flotats-Bastardas, Marina
    Gortner, Ludwig
    Zemlin, Michael
    Meyer, Sascha
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)